X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1030) 1030
Patent (18) 18
Book Chapter (5) 5
Conference Proceeding (3) 3
Magazine Article (2) 2
Book / eBook (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
physics, particles & fields (271) 271
experiment (233) 233
particle physics (200) 200
physics (185) 185
lep (146) 146
high energy physics (143) 143
e+e annihilation (132) 132
high energy physics - experiment (122) 122
physics - high energy physics - experiment (119) 119
detector (103) 103
particle physics - experiment (99) 99
microvertex detector (96) 96
phenomenology (81) 81
lund monte-carlo (78) 78
monte-carlo (72) 72
index medicus (70) 70
jet fragmentation (69) 69
ee (61) 61
bhabha scattering (55) 55
humans (54) 54
program (54) 54
physics, nuclear (50) 50
radiative-corrections (50) 50
cross-sections (49) 49
opal (49) 49
high-energies (48) 48
monte-carlo program (47) 47
astronomy & astrophysics (45) 45
female (44) 44
leptons (44) 44
male (44) 44
physics, multidisciplinary (43) 43
opal jet chamber (41) 41
opal detector (40) 40
nuclear experiment (39) 39
event generator (37) 37
fragmentation (37) 37
qcd (37) 37
2-photon production processes (36) 36
energies (36) 36
e+e-physics (34) 34
decays (32) 32
pair production (32) 32
daten (31) 31
elektron (31) 31
wechselwirkung (31) 31
arbeit (30) 30
collisions (30) 30
partikel (30) 30
positron (30) 30
standard model (30) 30
opal experiment (29) 29
modell (28) 28
elementary particles, quantum field theory (26) 26
middle aged (26) 26
nuclear physics, heavy ions, hadrons (26) 26
experimentelle daten (25) 25
e+e-annihilation (24) 24
zerfall (24) 24
elementarteilchen (23) 23
heavy quarks (23) 23
high-energy (23) 23
quarks (23) 23
z0 decays (23) 23
adult (22) 22
annihilation (22) 22
astrophysics (22) 22
hadron (22) 22
simulation (22) 22
teilchen (22) 22
aged (21) 21
photon corrections (21) 21
paarbildung (20) 20
z decays (20) 20
organic chemistry (19) 19
chemistry (18) 18
energy (18) 18
final-states (18) 18
mass (18) 18
metallurgy (18) 18
monte-carlo simulation (18) 18
quantum field theories, string theory (18) 18
acyclic or carbocyclic compounds (17) 17
analysis (17) 17
compositions based thereon (17) 17
decay (17) 17
macromolecular compounds obtained otherwise than by reactionsonly involving unsaturated carbon-to-carbon bonds (17) 17
organic macromolecular compounds (17) 17
root-s (17) 17
their preparation or chemical working-up (17) 17
fabrikation (16) 16
gammaover-bar (16) 16
hadrons (16) 16
luminosity (16) 16
2-photon processes (15) 15
astronomy, astrophysics and cosmology (15) 15
fizikai tudományok (15) 15
hadronic z decays (15) 15
lepton (15) 15
természettudományok (15) 15
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9982, pp. 2067 - 2076
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 22, pp. 2093 - 2104
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2015, Volume 372, Issue 25, pp. 2387 - 2397
In this trial, patients with an acute coronary syndrome within the previous 10 days were randomly assigned to simvastatin plus either ezetimibe or placebo. At... 
CHOLESTEROL ABSORPTION | CARDIAC OUTCOMES | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | CARDIOVASCULAR OUTCOMES | CLINICAL-TRIALS | SIMVASTATIN | PRIMARY PREVENTION | IMPROVE-IT | ATORVASTATIN | Simvastatin - therapeutic use | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Azetidines - adverse effects | Ezetimibe | Kaplan-Meier Estimate | Male | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - drug therapy | Anticholesteremic Agents - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Azetidines - therapeutic use | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Triglycerides - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Drug Therapy, Combination | Usage | Simvastatin | Analysis | Practice guidelines (Medicine) | Dosage and administration | Drug therapy, Combination | Acute coronary syndrome | Drug therapy | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Angina | Cholesterol | Intestine | Gallbladder | Acute coronary syndromes | Cardiovascular diseases | Statins | Pharmaceuticals | Cancer | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article